- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02053636
A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer (FINESSE)
An Open, 3-cohort, Phase II Trial Testing Oral Administration of Lucitanib in Patients With FGFR1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
East Melbourne, Australia
- Peter MacCallum Cancer Centre
-
Westmead, Australia, 2145
- Westmead Hospital
-
-
-
-
-
Brussels, Belgium, 1000
- Institut Jules Bordet
-
Bruxelles, Belgium, 1200
- Cliniques Universitaires St. Luc Oncology - Breast Clinic
-
Charleroi, Belgium, 6000
- Grand Hôpital de Charleroi Oncologie-Hématologie
-
Leuven, Belgium, 3000
- UZ Leuven Campus Gasthuisberg Dept. of General Medical
-
Namur, Belgium, 5000
- Clinique Sainte-Elisabeth Médecine Interne - Oncologie
-
-
-
-
-
Montreal, Canada, H2W 1S6
- McGill University Department of Oncologie - Clinical Reserach Program
-
Toronto, Canada, M5G 2M9
- Princess Margaret Cancer Centre
-
Toronto, Canada, M5G 2M9
- University Health Network - Princess Margaret Hospital
-
-
-
-
-
Toulouse, France, 31059
- Institut Claudius Regaud Dpt d'Oncologie Médicale
-
Villejuif, France, 94805
- Institut Gustave Roussy Dépt d'oncologie - Cancer du sein
-
Villejuif Cedex, France, 94805
- Institut Gustave Roussy
-
-
-
-
-
Essen, Germany, 45136
- Kliniken Essen-Mitte Klinik für Senologie - Brustzentrum
-
Offenbach, Germany, 63069
- Klinikum Offenbach
-
Offenbach, Germany, 63069
- KLINIKUM OFFENBACH Klinik für Gynäkologie und Geburtshilfe
-
-
-
-
-
Budapest, Hungary, 1122
- Orszagos Onkologiai Intezet Kemoterapia B es Klin.Farm.Oszt.
-
Debrecen, Hungary, 4032
- Debreceni Egyetem Orvos es Egeszsegtudomanyi Centrum Onkologiai Intezet
-
-
-
-
-
Milan, Italy, 20141
- Istituto Europeo di Oncologia
-
Milano, Italy, 20141
- Istituto Europeo di Oncologia Divisione Sviluppo Nuovi Farmaci per Terapie Innovative
-
-
-
-
-
Barcelona, Spain, 08035
- H. Valle de Hebrón Servicio de Oncología
-
Madrid, Spain, 08035
- Hospital Universitario Val d'Hebròn
-
Madrid, Spain, 28033
- MD Anderson Cancer Center Unidad de Investigación Clínica
-
Madrid, Spain, 28034
- H. Ramón y Cajal Servicio de Oncología Médica
-
Valencia, Spain, 46010
- H. Clínico de Valencia Servicio de Hematología y oncología Médica
-
-
-
-
-
Edinburgh, United Kingdom, EH4 2XU
- Western General Hospital Edinburgh Cancer Centre
-
London, United Kingdom, SW3 6JJ
- Royal Marsden Hospital
-
London, United Kingdom, SW3 6JJ
- The Royal Marsden NHS Trust Dpt of Medicine-Oncology
-
Nottingham, United Kingdom, NG5 1PB
- Nottingham University Hospitals NHS Trust Department of Clinical Oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed breast adenocarcinoma.
- Presence of an accessible metastatic lesion for biopsy or at least one archived metastatic tumour sample.
- Prior first-line systemic therapy in the metastatic setting.
- Demonstrated progression of disease by radiological or clinical assessment.
- Female patient, aged ≥18 years old.
- Estimated life expectancy >3 months.
- Normal Left ventricular function
- Adequate haematological, hepatic and renal functions.
- For women with childbearing potential, a negative pregnancy test prior to initiation of the study drug and willingness to use an effective contraception.
- Ability to swallow oral capsules or tablets.
Exclusion Criteria:
- More than two lines of chemotherapy with or without targeted therapy in the metastatic setting.
- Previous treatment with bevacizumab within 3 months of first dose of Investigational Medicinal Product.
- Active central nervous system metastases, cerebral oedema, and/or progressive growth.
- Patients with impaired cardiac function.
- Uncontrolled arterial hypertension
- Patients with history of thrombotic disorders or hereditary risk factors of thromboembolic events
- Serum potassium level below Lower Limit of Normal
- Uncontrolled hypothyroidism.
- Pregnant or breastfeeding women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: lucitanib
Hard gelatine capsules of 2,5, 5 and 10 mg or film coated tablets of 5 and 7,5 mg. 5 to 10 mg orally on a daily basis until unacceptable toxicity according to the investigator, disease progression or withdrawal of consent |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: Every 8 weeks
|
Tumor evaluation every 8 weeks throughout the study
|
Every 8 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Fabrice André, MD, Institut Gustave Roussy, France
- Study Chair: Javier Cortes, MD, Hospital Universitario Vall d'Hebrón, Spain
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL2-80881-001
- 2013-000288-10 (EudraCT Number)
- BIG 2-13 (Other Identifier: BIG)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).
They can ask all interventional clinical studies:
- submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
- Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
Clinical Trials on lucitanib
-
Teresa Helsten, MDClovis Oncology, Inc.WithdrawnAdvanced CancerUnited States
-
Clovis Oncology, Inc.TerminatedSmall Cell Lung Cancer | Non-Small Cell Lung Cancer | NSCLC | Lung Cancer | Metastatic Lung Cancer | SCLC | Stage IV Lung Cancer | Advanced Lung Cancer | Squamous Non-Small Cell Lung CancerUnited States, Italy, Germany, France, Spain
-
Haihe Biopharma Co., Ltd.Shanghai Institute of Materia Medica, Chinese Academy of SciencesCompleted
-
Institut de Recherches Internationales ServierCompletedSolid TumorsItaly, France, Spain
-
Clovis Oncology, Inc.TerminatedBreast Cancer | Metastatic Breast Cancer | Estrogen Receptor Positive | Triple Negative | HER2 | HER2 Positive | MBC | ERUnited States
-
Clovis Oncology, Inc.Bristol-Myers Squibb; European Network of Gynaecological Oncological Trial...SuspendedGynecologic Cancer | Advanced Solid TumorUnited States, Belgium, Spain, Germany, Austria, Italy
-
pharmaand GmbHGilead SciencesTerminatedOvarian Cancer | Solid Tumor | Urothelial Carcinoma | Triple-negative Breast CancerUnited States
-
Haihe Biopharma Co., Ltd.UnknownExtensive-stage Small Cell Lung CancerChina
-
Bristol-Myers SquibbEli Lilly and Company; Clovis Oncology, Inc.; ExelixisWithdrawnCarcinoma, Non-small Cell Lung CancerNetherlands, Norway, Belgium, Greece, United States, Argentina, Denmark, Mexico, Poland, Romania